Abstract | BACKGROUND AND AIM: METHODS: Normal volunteers (nine and 13 for two experiments, respectively) were enrolled. Salivary secretion, esophageal peristaltic contractions, and resting lower esophageal sphincter pressure with and without mosapride administration were recorded using a cross-over protocol. Post-prandial acidic and non-acidic reflux levels were also recorded. RESULTS:
Mosapride at a standard dose of 15 mg/day did not stimulate salivary secretion or any esophageal motor functions. It also failed to prevent acidic and non-acidic post-prandial gastroesophageal reflux. CONCLUSIONS:
Mosapride at 15 mg/day, a standard dose in Japan, did not change the esophageal motility and salivary secretion in healthy volunteers. Future study on a larger number of individuals with higher dose of mosapride is worthwhile.
|
Authors | Kenji Koshino, Kyoichi Adachi, Kenji Furuta, Shunji Ohara, Terumi Morita, Shuji Nakata, Takashi Tanimura, Masaharu Miki, Yoshikazu Kinoshita |
Journal | Journal of gastroenterology and hepatology
(J Gastroenterol Hepatol)
Vol. 25
Issue 6
Pg. 1066-71
(Jun 2010)
ISSN: 1440-1746 [Electronic] Australia |
PMID | 20594220
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Ulcer Agents
- Benzamides
- Morpholines
- Serotonin Receptor Agonists
- mosapride
|
Topics |
- Adult
- Anti-Ulcer Agents
- Benzamides
(administration & dosage)
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Electric Impedance
- Esophageal Sphincter, Lower
(drug effects, physiopathology)
- Esophageal pH Monitoring
- Esophagus
(drug effects, metabolism, physiopathology)
- Follow-Up Studies
- Gastroesophageal Reflux
(metabolism, physiopathology, prevention & control)
- Humans
- Male
- Manometry
- Morpholines
(administration & dosage)
- Peristalsis
(drug effects, physiology)
- Pressure
- Prognosis
- Reference Values
- Saliva
(metabolism)
- Serotonin Receptor Agonists
(administration & dosage)
|